Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology International"
DOI: 10.1007/s12072-018-9861-2
Abstract: IntroductionNew regimens involving direct-acting antiviral agents have recently been approved for the treatment of HCV. Our aim was to assess the efficacy and safety of 12 or 24 weeks of Sofosbuvir 400 mg plus Daclatasvir 60 mg, with… read more here.
Keywords: genotype patients; treatment; receiving weeks; without ribavirin ... See more keywords
The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24877
Abstract: Purpose To investigated the effectiveness of antiplatelet agents for the secondary prevention of stroke according to CYP2C19 genotype in patients with ischemic stroke (IS). Methods Between August 2009 and December 2011, 570 acute IS patients… read more here.
Keywords: genotype patients; primary outcome; secondary prevention; stroke according ... See more keywords